Atlas Trials

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D

Clinical trial NCT06829563 · RECRUITING

Trial details

NCT number
NCT06829563
Sponsor
Rezubio Pharmaceuticals Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Diabetes
Start date
2025-01-30
Primary completion
2025-12-20
Enrollment
134

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.